LLY

988.49

-0.8%↓

JNJ

201

-0.37%↓

ABBV

224.33

+0.44%↑

UNH

323.3

-0.19%↓

AZN

90.11

-1.1%↓

LLY

988.49

-0.8%↓

JNJ

201

-0.37%↓

ABBV

224.33

+0.44%↑

UNH

323.3

-0.19%↓

AZN

90.11

-1.1%↓

LLY

988.49

-0.8%↓

JNJ

201

-0.37%↓

ABBV

224.33

+0.44%↑

UNH

323.3

-0.19%↓

AZN

90.11

-1.1%↓

LLY

988.49

-0.8%↓

JNJ

201

-0.37%↓

ABBV

224.33

+0.44%↑

UNH

323.3

-0.19%↓

AZN

90.11

-1.1%↓

LLY

988.49

-0.8%↓

JNJ

201

-0.37%↓

ABBV

224.33

+0.44%↑

UNH

323.3

-0.19%↓

AZN

90.11

-1.1%↓

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

44.05 -0.79

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

43.43

Максимум

44.74

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+23.51% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	132M 3.4B
Предишно отваряне	44.84
Предишно затваряне	44.05

Настроения в новините

By Acuity

50%

166 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.12.2025 г., 23:48 ч. UTC

Значими двигатели на пазара

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8.12.2025 г., 23:44 ч. UTC

Пазарно говорене

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8.12.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8.12.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.12.2025 г., 23:13 ч. UTC

Пазарно говорене

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8.12.2025 г., 23:09 ч. UTC

Придобивния, сливания и поглъщания

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8.12.2025 г., 22:46 ч. UTC

Пазарно говорене

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8.12.2025 г., 22:01 ч. UTC

Пазарно говорене

Miners Poised to Do Well in 2026 -- Market Talk

8.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8.12.2025 г., 21:51 ч. UTC

Пазарно говорене

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

8.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

8.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.12.2025 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8.12.2025 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8.12.2025 г., 21:36 ч. UTC

Пазарно говорене

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8.12.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8.12.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8.12.2025 г., 21:08 ч. UTC

Пазарно говорене

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8.12.2025 г., 20:38 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8.12.2025 г., 20:26 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8.12.2025 г., 20:18 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8.12.2025 г., 20:07 ч. UTC

Пазарно говорене

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8.12.2025 г., 20:06 ч. UTC

Пазарно говорене

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8.12.2025 г., 20:05 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.12.2025 г., 20:05 ч. UTC

Пазарно говорене

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8.12.2025 г., 20:01 ч. UTC

Пазарно говорене

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

23.51% нагоре

12-месечна прогноза

Среден 55.59 USD 23.51%

Висок 65 USD

Нисък 44 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

166 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.